SCHEMBL4680139

SCHEMBL4680139

O=C(Cc1ccc(Cc2ccccn2)o1)C(=O)c1nc[nH]n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.36
TDP1 Q9NUW8 2/20 0.36
LMNA P02545 3/20 0.35
HRH3 Q9Y5N1 2/20 0.34
HRH4 Q9H3N8 1/20 0.34
TSHR P16473 3/20 0.34
RAB9A P51151 6/20 0.34
SMN1; SMN2 Q16637 4/20 0.34
NPC1 O15118 4/20 0.34
HPGD P15428 2/20 0.34
CASP3 P42574 2/20 0.34
SENP8 Q96LD8 2/20 0.34
SENP7 Q9BQF6 2/20 0.34
SENP6 Q9GZR1 2/20 0.34
MAPK1 P28482 2/20 0.34
MAPT P10636 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4678966 0.84 PTGER1 (0.35) TDP1SENP8SENP7SENP6
SCHEMBL4678675 0.83 FFAR2 (0.35) ALDH1A1TDP1LMNATSHRRAB9A
SCHEMBL4677011 0.82 TSHR (0.34) ALDH1A1TDP1LMNAHRH3HRH4
SCHEMBL5899365 0.82 TSHR (0.34) ALDH1A1TDP1LMNAHRH3HRH4
SCHEMBL4674021 0.81 SMN1; SMN2 (0.36) ALDH1A1TDP1LMNAHRH3HRH4
SCHEMBL4671677 0.81 LMNA (0.33) ALDH1A1LMNAHRH3HRH4TSHR
SCHEMBL4675326 0.81 ALDH1A1 (0.38) ALDH1A1LMNASMN1; SMN2MAPTPKM
SCHEMBL4672460 0.81 TSHR (0.36) ALDH1A1TDP1LMNAHRH3HRH4
SCHEMBL4677055 0.81 AR (0.33) ALDH1A1LMNARAB9ASMN1; SMN2NPC1
SCHEMBL4676103 0.80 RAB9A (0.36) ALDH1A1TDP1LMNAHRH3HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885TDP1 306/4885LMNA 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.